3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Not yet recruiting
2
Suspended
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Gemcitabine
42
130-nm albumin-bound paclitaxel
26
Albumin-Bound Paclitaxel
18
Irinotecan
16
Oxaliplatin
14
Fluorouracil
14
pembrolizumab
13
Nivolumab
13
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Taxes
10
Specimen Handling
9
Biopsy
9
Cisplatin
8
Capecitabine
7
folfirinox
6
Radiotherapy
6
Carboplatin
6
irinotecan sucrosofate
5
durvalumab
5
Ipilimumab
5
Cyclophosphamide
5
olaparib
4
defactinib
4
Surveys and Questionnaires
4
Standard of Care
4
Radiosurgery
4
Immunoglobulin G
4
Disulfides
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pancreatic Neoplasms
×
zimberelimab
×
Clear all
NCT04104672
2026-06-02
ARC-8
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
196 enrolled